Study Shows Promise of Lipid Nanoparticle-Based Treatment for Oral Cancer
A study presented at the 102nd General Session of the International Association for Dental, Oral, and Craniofacial Research, in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for Dental Research, showcased the development of a lipid nanoparticles (LNP) platform for treating oral squamous cell carcinoma (OSCC) utilizing p53 mRNA. Conducted by Marshall Scott Padilla, PhD, from the University of Pennsylvania, the study involved formulating a library of LNPs with luciferase mRNA and testing them in OSCC cells and mice models. The lead candidate, LNP E10i-494, demonstrated significant mRNA transfection in vitro and in mice tumor models, with low liver transfection, indicating a promising safety profile. Furthermore, in an orthotopic model, E10i-494 effectively entered and transfected lymph nodes, crucial for preventing tumor metastasis. Additionally, when reformulated with p53 mRNA, E10i-494 exhibited potent cell killing. The study concluded that the optimized LNP represents a significant advancement in oral cancer therapy, particularly for p53-based OSCC treatment. Click here to read more.
